D-Index & Metrics Best Publications

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Biology and Biochemistry D-index 68 Citations 19,086 225 World Ranking 3333 National Ranking 1714
Medicine D-index 83 Citations 26,130 293 World Ranking 8303 National Ranking 4523

Research.com Recognitions

Awards & Achievements

2008 - Fellow of the American Association for the Advancement of Science (AAAS)

Overview

What is he best known for?

The fields of study he is best known for:

  • Cancer
  • Internal medicine
  • Gene

His main research concerns Interferon, Immunology, Internal medicine, Cancer research and Molecular biology. His Interferon research incorporates elements of Biochemistry, Cell cycle, Macrophage, Pharmacology and Indoleamine 2,3-dioxygenase. He usually deals with Immunology and limits it to topics linked to Mechanism of action and Signal transduction, Cell culture, Allogeneic Lymphocyte and Hairy cell leukemia.

His Internal medicine research integrates issues from Surgery, Endocrinology, Alpha interferon and Oncology. His specific area of interest is Cancer research, where Ernest C. Borden studies Melanoma. His studies in Molecular biology integrate themes in fields like Peripheral blood mononuclear cell, In vitro, Interferon gamma, Lymphocyte and Monocyte.

His most cited work include:

  • Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. (1741 citations)
  • Interferons at age 50: past, current and future impact on biomedicine. (839 citations)
  • Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033 (772 citations)

What are the main themes of his work throughout his whole career to date?

Interferon, Immunology, Cancer research, Internal medicine and Melanoma are his primary areas of study. His Interferon study integrates concerns from other disciplines, such as Molecular biology, In vitro, Biochemistry and Pharmacology. The Molecular biology study combines topics in areas such as Lymphokine-activated killer cell and Lymphocyte.

His Immunology study often links to related topics such as Peripheral blood mononuclear cell. His Cancer research study deals with Pathology intersecting with Circulating tumor cell. His biological study spans a wide range of topics, including Endocrinology, Alpha interferon and Oncology.

He most often published in these fields:

  • Interferon (30.00%)
  • Immunology (30.54%)
  • Cancer research (27.57%)

What were the highlights of his more recent work (between 2009-2020)?

  • Cancer research (27.57%)
  • Cancer (12.43%)
  • Melanoma (17.03%)

In recent papers he was focusing on the following fields of study:

His scientific interests lie mostly in Cancer research, Cancer, Melanoma, Internal medicine and Oncology. The concepts of his Cancer research study are interwoven with issues in Interferon, Pathology, Receptor, Signal transduction and Programmed cell death. His Interferon research is multidisciplinary, incorporating elements of Flow cytometry and Gene.

His Melanoma research incorporates themes from Cell growth, Immunology, Immune system, Renal cell carcinoma and In vivo. Ernest C. Borden interconnects Endocrinology, Medical physics and Sarcoma in the investigation of issues within Internal medicine. His Oncology study combines topics in areas such as Clinical trial, Phases of clinical research, Survival rate, Surgery and Apoptosis.

Between 2009 and 2020, his most popular works were:

  • Oxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligands (311 citations)
  • Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma (224 citations)
  • Defining the critical hurdles in cancer immunotherapy (132 citations)

In his most recent research, the most cited papers focused on:

  • Cancer
  • Gene
  • Internal medicine

Ernest C. Borden mostly deals with Cancer research, Melanoma, Internal medicine, Interferon and Immune system. Ernest C. Borden combines subjects such as Histone deacetylase, Histone deacetylase 5, Signal transduction and Autocrine signalling with his study of Cancer research. His Melanoma research incorporates elements of Open Resection, Endoscopy and In vivo.

His research integrates issues of Virus, Endocrinology and Oncology in his study of Internal medicine. His Interferon research focuses on Gene and how it connects with Cytokine, Cell type and Cancer cell. His Immune system study introduces a deeper knowledge of Immunology.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

John M. Kirkwood;Myla Hunt Strawderman;Marc S. Ernstoff;Thomas J. Smith.
Journal of Clinical Oncology (1996)

2565 Citations

Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033

Charles D. Blanke;Cathryn Rankin;George D. Demetri;Christopher W. Ryan.
Journal of Clinical Oncology (2008)

1220 Citations

Interferons at age 50: past, current and future impact on biomedicine.

Ernest C Borden;Ganes Sen;Gilles Uze;Robert H Silverman.
Nature Reviews Drug Discovery (2007)

1173 Citations

Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis.

Mamta Chawla-Sarkar;Daniel J Lindner;Y-F Liu;Bryan Raymond George Williams.
Apoptosis (2003)

966 Citations

Circulating Tumor Cells versus Imaging—Predicting Overall Survival in Metastatic Breast Cancer

G. Thomas Budd;Massimo Cristofanilli;Mathew J. Ellis;Allison Stopeck.
Clinical Cancer Research (2006)

867 Citations

Inhibition of Angiogenesis by Interferons: Effects on Tumor-and Lymphocyte-induced Vascular Responses

Younan A. Sidky;Ernest C. Borden.
Cancer Research (1987)

771 Citations

Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.

Michael C. Heinrich;Kouros Owzar;Christopher L. Corless;Donna Hollis.
Journal of Clinical Oncology (2008)

715 Citations

Biological Properties of Recombinant α-Interferons: 40th Anniversary of the Discovery of Interferons

Lawrence M. Pfeffer;Charles A. Dinarello;Ronald B. Herberman;Bryan R. G. Williams.
Cancer Research (1998)

647 Citations

Soft Tissue Sarcomas of Adults State of the Translational Science

Ernest C. Borden;Laurence H. Baker;Robert S. Bell;Vivien Bramwell.
Clinical Cancer Research (2003)

555 Citations

Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis.

M Chawla-Sarkar;S I Bae;F J Reu;B S Jacobs.
Cell Death & Differentiation (2004)

438 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Ernest C. Borden

John M. Kirkwood

John M. Kirkwood

University of Pittsburgh

Publications: 117

Jean-Yves Blay

Jean-Yves Blay

Claude Bernard University Lyon 1

Publications: 80

Dietmar Fuchs

Dietmar Fuchs

Innsbruck Medical University

Publications: 71

Axel Le Cesne

Axel Le Cesne

Institut Gustave Roussy

Publications: 52

Vernon K. Sondak

Vernon K. Sondak

University of South Florida

Publications: 51

Alexander M.M. Eggermont

Alexander M.M. Eggermont

Erasmus University Rotterdam

Publications: 50

Paolo G. Casali

Paolo G. Casali

University of Milan

Publications: 49

Axel Hauschild

Axel Hauschild

Kiel University

Publications: 48

Alessandro Gronchi

Alessandro Gronchi

University of Milan

Publications: 46

Douglas S. Reintgen

Douglas S. Reintgen

University of South Florida

Publications: 45

Leonidas C. Platanias

Leonidas C. Platanias

Northwestern University

Publications: 44

Robert G. Maki

Robert G. Maki

University of Pennsylvania

Publications: 44

Piotr Rutkowski

Piotr Rutkowski

Maria Sklodowska-Curie National Research Institute of Oncology

Publications: 41

Ian Judson

Ian Judson

Institute of Cancer Research

Publications: 41

Massimo Cristofanilli

Massimo Cristofanilli

Northwestern University

Publications: 41

Michael Heinrich

Michael Heinrich

Oregon Health & Science University

Publications: 40

Trending Scientists

Engin Kirda

Engin Kirda

Northeastern University

Behnam Fahimnia

Behnam Fahimnia

University of Sydney

David M. Pennock

David M. Pennock

Rutgers, The State University of New Jersey

Taghi M. Khoshgoftaar

Taghi M. Khoshgoftaar

Florida Atlantic University

George Tchobanoglous

George Tchobanoglous

University of California, Davis

Tasneem Abbasi

Tasneem Abbasi

Pondicherry University

Peter Wasserscheid

Peter Wasserscheid

University of Erlangen-Nuremberg

Wolfgang Brütting

Wolfgang Brütting

University of Augsburg

James N. Long

James N. Long

Utah State University

James G. McNally

James G. McNally

National Institutes of Health

Teruo Nishida

Teruo Nishida

Yamaguchi University

Masaru Katoh

Masaru Katoh

University of Pennsylvania

Melvin Cohn

Melvin Cohn

Salk Institute for Biological Studies

Joseph P. Montoya

Joseph P. Montoya

Georgia Institute of Technology

Sara R. Jones

Sara R. Jones

Wake Forest University

Krzysztof Selmaj

Krzysztof Selmaj

University of Warmia and Mazury in Olsztyn

Something went wrong. Please try again later.